ESTRO 2024 - Abstract Book

S830

Clinical - CNS

ESTRO 2024

2. CHANG, E. L., WEFEL, J. S., HESS, K. R., ALLEN, P. K., LANG, F. F., KORNGUTH, D. G., ARBUCKLE, R. B., SWINT, J. M., SHIU, A. S., MAOR, M. H. & MEYERS, C. A. 2009. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. The Lancet Oncology, 10, 1037-1044. 3. GONDI, V., HERMANN, B. P., MEHTA, M. P. & TOME, W. A. 2012. Hippocampal dosimetry predicts neurocognitive function impairment after fractionated stereotactic radiotherapy for benign or low-grade adult brain tumors. Int J Radiat Oncol Biol Phys, 83, e487-93. 4. CHANG, J. S., MA, L., BARANI, I. J., MCDERMOTT, M. W., SNEED, P. K. & LARSON, D. A. 2016. Hippocampal Dose With Radiosurgery for Multiple Intracranial Targets: The Rationale for Proactive Beam Shaping. Technology in cancer research & treatment, 15, 555-559.

5. GONDI, V., TOME, W. A., ROWLEY, H. A. & MEHTA, M. P. 2014b. Hippocampal Contouring: A Contouring Atlas for RTOG 0933.

1154

Digital Poster

Survival impact of early MRI relapse in a cohort of 540 patients treated with brain stereotactic RT

Moncef Morjani 1 , François Lucia 1,2 , Brieg Dissaux 3,4 , Olivier Pradier 1,2 , Gurvan Dissaux 1,5 , Vincent Bourbonne 1,2

1 University Hospital, Radiation Oncology, Brest, France. 2 INSERM, LaTIM UMR 1101, Brest, France. 3 University Hospital, Radiology, Brest, France. 4 INSERM, GETBO UMR 1304, Brest, France. 5 INSERM, LaTIM UMR 1101, Brestf, France

Purpose/Objective:

Remnographic follow-up after stereotactic radiotherapy (SRT) is crucial to identify early regional progression. The aim of the study was to determine the survival impact of the remnographic reassessment. The primary endpoint was the overall survival (OS) impact of regional progression at MRI_1 (defined as the first MRI performed post-SRT).

Material/Methods:

We retrospectively analyzed 681 adult patients with solid cancer with brain metastases treated with hypofractionated SRT at the Brest University Hospital between 01/01/2014 and 07/15/2022. We then selected only patients who had an avalaible MRI_1 and for whom it was possible to calculate the DS-GPA score, thus obtaining 685 treatment courses and 540 patients (869 brain metastases).

Results: